Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at firstname.lastname@example.org.
For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
|NCT02166905||II||NY-ESO-1 or LAGE-1+ ovarian cancer with or without residual disease after treatment||A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen||View Drugs||New York|
|CDX-1401||DEC-205/NY-ESO-1 fusion protein CDX-1401||Immune response against cancer expressing NY-ESO-1|
|Epacadostat||3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360||Inhibits IDO1 to stimulate immune response|